Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


COVID-19: Daily Top 10 Papers


  Malignant Melanoma

  Free Subscription


Articles published in Br J Cancer

Retrieve available abstracts of 34 articles:
HTML format



Single Articles


    November 2021
  1. HAMIS SJ, Kapelyukh Y, McLaren A, Henderson CJ, et al
    Quantifying ERK activity in response to inhibition of the BRAFV600E-MEK-ERK cascade using mathematical modelling.
    Br J Cancer. 2021;125:1552-1560.
    PubMed     Abstract available


    October 2021
  2. HASSEL JC
    Checkpoint blocker induced autoimmunity as an indicator for tumour efficacy in melanoma.
    Br J Cancer. 2021 Oct 25. pii: 10.1038/s41416-021-01390.
    PubMed     Abstract available


    August 2021
  3. MARSAVELA G, McEvoy AC, Pereira MR, Reid AL, et al
    Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression.
    Br J Cancer. 2021 Aug 9. pii: 10.1038/s41416-021-01507.
    PubMed     Abstract available


    July 2021
  4. BOUCHEREAU S, Chaplain L, Fort M, Beauchet A, et al
    Impact of prior treatment with immune checkpoint inhibitors on dacarbazine efficacy in metastatic melanoma.
    Br J Cancer. 2021 Jul 14. pii: 10.1038/s41416-021-01486.
    PubMed     Abstract available


    June 2021
  5. MAIQUES O, Fanshawe B, Crosas-Molist E, Rodriguez-Hernandez I, et al
    A preclinical pipeline to evaluate migrastatics as therapeutic agents in metastatic melanoma.
    Br J Cancer. 2021 Jun 25. pii: 10.1038/s41416-021-01442.
    PubMed     Abstract available


    May 2021
  6. WEBER A, Leitzmann MF, Sedlmeier AM, Baurecht H, et al
    Association between physical activity, grip strength and sedentary behaviour with incidence of malignant melanoma: results from the UK Biobank.
    Br J Cancer. 2021 May 31. pii: 10.1038/s41416-021-01443.
    PubMed     Abstract available


    April 2021
  7. DHOMEN N, Mundra PA, Marais R
    Sunglasses to hide behind may also prevent melanoma of the eyes.
    Br J Cancer. 2021 Apr 6. pii: 10.1038/s41416-021-01343.
    PubMed     Abstract available


  8. WANG H, Elsheikh M, Gilmour K, Cohen V, et al
    Impact of COVID-19 pandemic on eye cancer care in United Kingdom.
    Br J Cancer. 2021;124:1357-1360.
    PubMed     Abstract available


    March 2021
  9. VAN BREESCHOTEN J, Wouters MWJM, Hilarius DL, Haanen JB, et al
    Correction: First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01312.
    PubMed    


  10. YE W, Olsson-Brown A, Watson RA, Cheung VTF, et al
    Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
    Br J Cancer. 2021 Mar 15. pii: 10.1038/s41416-021-01310.
    PubMed     Abstract available


  11. YAO S, Janku F, Subbiah V, Stewart J, et al
    Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.
    Br J Cancer. 2021 Mar 5. pii: 10.1038/s41416-020-01230.
    PubMed     Abstract available


  12. KATO R, Haratani K, Hayashi H, Sakai K, et al
    Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts.
    Br J Cancer. 2021;124:914-924.
    PubMed     Abstract available


    February 2021
  13. BARCLAY ME, Abel GA, Greenberg DC, Rous B, et al
    Socio-demographic variation in stage at diagnosis of breast, bladder, colon, endometrial, lung, melanoma, prostate, rectal, renal and ovarian cancer in England and its population impact.
    Br J Cancer. 2021 Feb 9. pii: 10.1038/s41416-021-01279.
    PubMed     Abstract available


    January 2021
  14. VAN BREESCHOTEN J, Wouters MWJM, Hilarius DL, Haanen JB, et al
    First-line BRAF/MEK inhibitors versus anti-PD-1 monotherapy in BRAF(V600)-mutant advanced melanoma patients: a propensity-matched survival analysis.
    Br J Cancer. 2021 Jan 26. pii: 10.1038/s41416-020-01229.
    PubMed     Abstract available


    December 2020
  15. AMERATUNGA M, Brana I, Bono P, Postel-Vinay S, et al
    First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
    Br J Cancer. 2020;123:1730-1736.
    PubMed     Abstract available


    November 2020
  16. KUMAR PR, Moore JA, Bowles KM, Rushworth SA, et al
    Mitochondrial oxidative phosphorylation in cutaneous melanoma.
    Br J Cancer. 2020 Nov 18. pii: 10.1038/s41416-020-01159.
    PubMed     Abstract available


  17. SMITH AJ, Lambert PC, Rutherford MJ
    Understanding the impact of sex and stage differences on melanoma cancer patient survival: a SEER-based study.
    Br J Cancer. 2020 Nov 4. pii: 10.1038/s41416-020-01144.
    PubMed     Abstract available


    October 2020
  18. BHAVE P, Pallan L, Long GV, Menzies AM, et al
    Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
    Br J Cancer. 2020 Oct 22. pii: 10.1038/s41416-020-01121.
    PubMed     Abstract available


  19. PAMIDIMUKKALA N, Puts GS, Kathryn Leonard M, Snyder D, et al
    Nme1 and Nme2 genes exert metastasis-suppressor activities in a genetically engineered mouse model of UV-induced melanoma.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01096.
    PubMed     Abstract available


  20. RABBIE R, Ferguson P, Wong K, Couturier DL, et al
    The mutational landscape of melanoma brain metastases presenting as the first visceral site of recurrence.
    Br J Cancer. 2020 Oct 7. pii: 10.1038/s41416-020-01090.
    PubMed     Abstract available


    August 2020
  21. TREMBLE LF, McCabe M, Walker SP, McCarthy S, et al
    Differential association of CD68(+) and CD163(+) macrophages with macrophage enzymes, whole tumour gene expression and overall survival in advanced melanoma.
    Br J Cancer. 2020 Aug 26. pii: 10.1038/s41416-020-01037.
    PubMed     Abstract available


  22. ALMEIDA RR, Vieira RS, Castoldi A, Terra FF, et al
    Host dysbiosis negatively impacts IL-9-producing T-cell differentiation and antitumour immunity.
    Br J Cancer. 2020;123:534-541.
    PubMed     Abstract available


    July 2020
  23. MIDDLETON MR, Hoeller C, Michielin O, Robert C, et al
    Intratumoural immunotherapies for unresectable and metastatic melanoma: current status and future perspectives.
    Br J Cancer. 2020 Jul 27. pii: 10.1038/s41416-020-0994.
    PubMed     Abstract available


  24. CHEUNG VTF, Gupta T, Olsson-Brown A, Subramanian S, et al
    Immune checkpoint inhibitor-related colitis assessment and prognosis: can IBD scoring point the way?
    Br J Cancer. 2020;123:207-215.
    PubMed     Abstract available


    April 2020
  25. TROIANI T, Giunta EF, Tufano M, Vigorito V, et al
    Alternative macrophage polarisation associated with resistance to anti-PD1 blockade is possibly supported by the splicing of FKBP51 immunophilin in melanoma patients.
    Br J Cancer. 2020 Apr 22. pii: 10.1038/s41416-020-0840.
    PubMed     Abstract available


  26. MCNEILLIS R, Greystoke A, Walton J, Bacon C, et al
    A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965.
    Br J Cancer. 2020;122:1141-1145.
    PubMed     Abstract available


    February 2020
  27. GRANADOS K, Huser L, Federico A, Sachindra S, et al
    T-type calcium channel inhibition restores sensitivity to MAPK inhibitors in de-differentiated and adaptive melanoma cells.
    Br J Cancer. 2020 Feb 17. pii: 10.1038/s41416-020-0751.
    PubMed     Abstract available


  28. SPAIN L, Larkin J, Turajlic S
    New survival standards for advanced melanoma.
    Br J Cancer. 2020 Feb 17. pii: 10.1038/s41416-020-0738.
    PubMed    


  29. AYA-BONILLA CA, Morici M, Hong X, McEvoy AC, et al
    Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells.
    Br J Cancer. 2020 Feb 10. pii: 10.1038/s41416-020-0750.
    PubMed     Abstract available


    January 2020
  30. TIAGO M, Capparelli C, Erkes DA, Purwin TJ, et al
    Targeting BRD/BET proteins inhibits adaptive kinome upregulation and enhances the effects of BRAF/MEK inhibitors in melanoma.
    Br J Cancer. 2020 Jan 14. pii: 10.1038/s41416-019-0724.
    PubMed     Abstract available


    December 2019
  31. ICE RJ, Chen M, Sidorov M, Le Ho T, et al
    Drug responses are conserved across patient-derived xenograft models of melanoma leading to identification of novel drug combination therapies.
    Br J Cancer. 2019 Dec 20. pii: 10.1038/s41416-019-0696.
    PubMed     Abstract available


  32. GUPTA A, Towers C, Willenbrock F, Brant R, et al
    Dual-specificity protein phosphatase DUSP4 regulates response to MEK inhibition in BRAF wild-type melanoma.
    Br J Cancer. 2019 Dec 16. pii: 10.1038/s41416-019-0673.
    PubMed     Abstract available


  33. DELGADO-GONI T, Galobart TC, Wantuch S, Normantaite D, et al
    Increased inflammatory lipid metabolism and anaplerotic mitochondrial activation follow acquired resistance to vemurafenib in BRAF-mutant melanoma cells.
    Br J Cancer. 2019 Dec 10. pii: 10.1038/s41416-019-0628.
    PubMed     Abstract available


    February 2019
  34. LIU C, He H, Li X, Su MA, et al
    Dynamic metrics-based biomarkers to predict responders to anti-PD-1 immunotherapy.
    Br J Cancer. 2019;120:346-355.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: